Reston, Va.—The Journal of Nuclear Medicine (JNM)—the top-rated medical imaging journal worldwide—has published Multimodality Molecular Imaging of the Cardiovascular System, presenting the state of the art of cardiovascular molecular imaging and discussing opportunities and challenges in advancing cardiovascular molecular imaging to clinical practice.
"Cardiovascular molecular imaging is still a relatively novel field," said Heinrich R. Schelbert, M.D., Ph.D., editor-in-chief of JNM. "The supplement represents a composite of the work being done—which will help us to understand more than we have ever known about the heart and will pave the way for future research."
This peer-reviewed supplement, available in May 2010, provides in-depth research on a broad range of topics related to cardiovascular molecular imaging and combines the work of several scientific communities—including radiology, cardiology and nuclear medicine—to provide a comprehensive overview of this emerging field.
"The creation of multidisciplinary basic and translational research teams that employ cellular and molecular imaging will lead to improved management of cardiovascular disease," said Albert J. Sinusas, M.D., director of cardiovascular imaging at Yale University in New Haven, Conn., and guest editor of the JNM supplement.
Articles in the new publication investigate topics that cover the entire spectrum of technology currently used to visualize the heart, including ultrasound, MRI, radiotracers, novel probes and other advances in instrumentation. Some articles discuss the use of intravascular devices that go inside the heart, while others approach the heart from noninvasive imaging perspectives. Also covered are areas of great potential, such as stem cell therapy and the introduction of nanoparticles for "theranostics"—the combination of diagnostics and therapy for drug delivery. Several research articles examine multiple methods of imaging the heart as it goes through the repair process following a heart attack called "remodeling."
The supplement also examines the role of molecular imaging in explaining the cellular processes that underlie prevalent heart diseases, such as atherosclerosis (hardening of the artery walls). With better understanding of the molecular biology of atherosclerosis, researchers hope to be able to diagnose it in its earliest stages.
"These studies were conducted with the goal of understanding how to prevent diseases that affect the heart by detecting them before they manifest," said Sinusas. "Another goal was to identify individual risk factors so that physicians can direct patients to the right therapy and use imaging to evaluate whether that therapy is working."
Credentialed media: To obtain copies of the articles published in the supplement—and online access to The Journal of Nuclear Medicine—please contact Amy Shaw at (703) 652-6773 or ashaw@snm.org, or Jane Kollmer at (703) 326-1184 or jkollmer@snm.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org. A subscription to the journal is an SNM member benefit.
About SNM—Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snm.org.
Journal
Journal of Nuclear Medicine